EUVIMEDEUVIMED entdecken
Crossref

1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4)

LIMING CHEN, MALIK BENAMAR, BENJAMIN HILLIGSØE HARVEY, SIN GON KIM, LAURA PLETSCH BORBA, PAOLO FIORINA

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1752-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LIMING CHEN und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: COMBINE 4 compared the efficacy and safety of IcoSema, a once-weekly combination of insulin icodec + semaglutide, vs once-daily glargine U100 in insulin-naïve adults with T2D. At week 40, the change from baseline in Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) total treatment satisfaction score (TTSS) was statistically significantly greater with IcoSema vs glargine U100. Here, we consider individual DTSQs items contributing to the TTSS.

Methods

COMBINE 4 was a 40-week, open-label, treat-to-target, phase 3b trial. Adults (≥ 18 years) with T2D (A1C ≥ 8.0%) on oral glucose-lowering medications were randomized 1:1 to IcoSema (n=243) or glargine U100 (n=242). DTSQs was completed at baseline and week 40.

Results

At week 40, changes from baseline in all contributing DTSQs item scores were statistically significantly greater with IcoSema vs glargine U100 (Fig. A). The odds of achieving a clinically meaningful change in DTSQs TTSS, and in item scores for convenience and flexibility, were statistically significantly greater with IcoSema vs glargine U100; all other contributing item EORs numerically favored IcoSema (Fig. B).

Conclusion

The statistically significantly greater change in DTSQs TTSS in favor of IcoSema vs glargine U100 was driven by improvements in all contributing items. Disclosure L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi. M. Benamar: Employee; Current; Novo Nordisk A/S. B. Harvey: Employee; Current; Novo Nordisk A/S. S. Kim: None. L. Pletsch Borba: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Novo Nordisk A/S. P. Fiorina: Board Member; Ended; Novo Nordisk, Lilly, AstraZeneca, Boehringer Ingelheim International GmbH.

Zitieren

APA

CHEN, L., BENAMAR, M., HARVEY, B. H., KIM, S. G., BORBA, L. P., & FIORINA, P. (2026). 1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4). Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1752-p

Vancouver

CHEN L, BENAMAR M, HARVEY BH, KIM SG, BORBA LP, FIORINA P. 1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4). Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1752-p

BibTeX
@article{CHEN2026,
  author = {CHEN, LIMING and BENAMAR, MALIK and HARVEY, BENJAMIN HILLIGSØE and KIM, SIN GON and BORBA, LAURA PLETSCH and FIORINA, PAOLO},
  title = {1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4)},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1752-p}
}
Kostenlos starten →